Craft

Bolt Biotherapeutics

Stock Price

$0.7

2024-06-18

Market Capitalization

$28 M

2024-06-18

Revenue

$7.9 M

FY, 2023

Bolt Biotherapeutics Summary

Company Summary

Overview
Bolt Biotherapeutics is a biotechnology company developing immunotherapeutics for multiple types of cancer. Its Immune-stimulating Antibody Conjugates (ISAC) eliminate tumors following systemic administration in preclinical studies and results in the development of immunological memory. The company also develops Myeloid Modulator Platform that reawakens myeloid cells to attack tumor cells.
Type
Public
Status
Active
Founded
2015
HQ
Redwood City, CA, US | view all locations
Website
http://boltbio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Randall Schatzman

    Randall Schatzman, Chief Executive Officer and Board Member

  • Grant Yonehiro

    Grant Yonehiro, Chief Business Officer

  • Edith A. Perez

    Edith A. Perez, Chief Medical Officer

  • William P. Quinn

    William P. Quinn, Chief Financial Officer

Operating MetricsView all

Patents (US)

1

FY, 2020

Co-Owned Patent Applications (US)

21

FY, 2020

Co-Owned Patent Applications (Foreign)

50

FY, 2020

LocationsView all

1 location detected

  • Redwood City, CA HQ

    United States

    900 Chesapeake Dr

Bolt Biotherapeutics Financials

Summary Financials

Revenue (Q1, 2024)
$5.3M
Net income (Q1, 2024)
($10.8M)
Cash (Q1, 2024)
$4.3M
EBIT (Q1, 2024)
($17.1M)
Enterprise value
$43.3M

Footer menu